Q-omics provides the consensus-scored RBM14-RBM4 profile across patient tissues and cancer cell-line models. RBM14-RBM4 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, RBM14-RBM4 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, RBM14-RBM4 RNA expression shows 20,552 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, COAD, and ACC as cancer lineages where RBM14-RBM4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBM14-RBM4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBM14-RBM4 survival associations across molecular data types. RBM14-RBM4 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBM14-RBM4 RNA expression–survival associations across cancer types. High RBM14-RBM4 expression shows unfavorable associations in KICH, ACC, KIRC and COAD, but favorable associations in UCS and THYM. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for RBM14-RBM4 RNA expression.
This table summarizes RBM14-RBM4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RBM14-RBM4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBM14-RBM4 shows lower tumor expression in THCA and higher tumor expression in COAD, HNSC, LUSC, BRCA and LIHC. The COAD box plot shows higher RBM14-RBM4 RNA expression in tumor versus normal tissue (log2 FC = +0.428, t-test p < 0.001).
This table shows molecular features associated with RBM14-RBM4 in patient tissues and cancer cell lines. In patient samples, RBM14-RBM4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RBM14-RBM4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LUNG_NSCLC_LUAD.
